Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche puts Genentech in context

Executive Summary

"We consolidate not only Genentech sales but also all the Genentech expenses in our P&L," Roche CEO Franz Humer tells Aug. 15 conference call. "We are really in that sense looking at Genentech sales as products which in the U.S. we simply sell through a different sales organization, but it is one Roche company"

You may also be interested in...

Roche Tries Genentech Formula In Japan: Chugai Deal Follows 1990 Model

Roche will have "opt-in" rights on Chugai's Phase II rheumatoid arthritis agent in the U.S. as part of the merger agreement between the two firms

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts